Arkansas Law Review
Volume 70

Number 3

Article 5

December 2017

Zika, Pregnancy, and the Law
Sam F. Halabi
University of Missouri

Follow this and additional works at: https://scholarworks.uark.edu/alr
Part of the Health Law and Policy Commons, Maternal and Child Health Commons, and the Women's
Health Commons

Recommended Citation
Sam F. Halabi, Zika, Pregnancy, and the Law, 70 Ark. L. Rev. 707 (2017).
Available at: https://scholarworks.uark.edu/alr/vol70/iss3/5

This Essay is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion
in Arkansas Law Review by an authorized editor of ScholarWorks@UARK. For more information, please contact
scholar@uark.edu.

ZIKA, PREGNANCY, AND THE LAW
Sam F. Halabi ∗

I. INTRODUCTION
The public health emergency surrounding the spread of the
Zika virus has resurrected and brought into sharp relief some of
the most vexing questions surrounding the relationship between
pregnancy and law: the appropriate circumstances, if any, in
which fetal tissue research is permissible; 1 when and how the
government may sponsor statements intended to influence
reproductive decisions; 2 and how to balance the health and rights
of both women and their unborn children when health threats
target both. 3 This latter question has come to the forefront in the
∗
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1. Erika Check Hayden, Zika Highlights Role of Fetal-Tissue Research, 532 NATURE
16, 16 (2016), https://www.nature.com /polopoly_fs /1.19655! /menu /main / topColumns
/topLeftColumn/pdf/nature.2016.19655.pdf
[https://perma.cc/J5RM-Q2DH];
Doug
Wassenaar, Ethics Considerations in Zika Vaccine Research: An Approach, WORLD
HEALTH ORG. (June 7, 2016),
http://www.who.int /
immunization /research
/meetings_workshops /2_Douglas_Wassenaar_zika_june_16.pdf [https://perma.cc/7NH48LLJ]; Julie Steenhuysen, Researchers Find New Zika Clues to Birth Defect in Fetus Study,
REUTERS, Feb. 10, 2016, http://www.reuters.com /article /us-health-zika-scienceidUSKCN0VJ2M7 [https://perma.cc/R47W-XM2Y].
2. RUTH MACKLIN, ETHICS IN GLOBAL HEALTH: RESEARCH, POLICY, AND PRACTICE
50 (2012) (noting influence of governments in shaping reproductive decisions); see generally
Zika: How to Communicate Effectively, CTRS. FOR DISEASE CONTROL & PREVENTION:
ZIKA ACTION PLAN SUMMIT (Apr. 2016), https://www.cdc.gov/zap/pdfs/presentations/zapcommunicate-effectively.pdf [https://perma.cc/EAN5-USRS]; Robert P.S. Jansen,
Evidence-Based Ethics and Regulation of Reproduction, 12 HUM. REPROD. 2068 (1997),
https://doi.org/
10.1093/humrep/12.9.2068 [https://perma.cc/H5Y2-56MZ]
(detailing
historical ethical difficulties between government sponsorship and reproductive choice).
3. AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS, COMM. OP. NO. 563, ETHICAL
ISSUES IN PANDEMIC INFLUENZA PLANNING CONCERNING PREGNANT WOMEN 1-2 (2013,
reaff’d
2016),
https://www.acog.org/Resources-And-Publications/
CommitteeOpinions/Committee-on-Ethics/Ethical-Issues-in-Pandemic-Influenza-PlanningConcerning-Pregnant-Women [https://perma.cc/VT7H-8L38].
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Zika context. Because the virus inflicts its heaviest known toll in
utero, research undertaken for treatments or vaccines will
inevitably implicate application of that research to pregnant
women. 4
Yet the Zika public health emergency also arises at a time in
which legal scholars have recently launched a reevaluation,
reexamination, and reimagination of the relationship between
pregnancy and law across a number of fields including criminal
law, disability law, poverty law, and employment discrimination,
among others. Broadly speaking, these scholars assert that
legislatures, courts, and regulators have “essentialized”
pregnancy—reducing it to factors specific to gestation—in ways
that undermine pregnant women’s rights to work, 5 disrespect or
unequally burden their autonomy under statutory regimes
informed and shaped by Roe v. Wade, 6 and arbitrarily subject
pregnant women to penal statutes in both the civil and criminal
contexts. 7 The debate under way is not limited to the academy:
both Hillary Clinton and Donald Trump campaigned in part on
4. See generally Jon Cohen, The Race for a Zika Vaccine is On, 351 SCIENCE 543
(2016), http://science.sciencemag.org/content/351/6273/543 [https://perma.cc/ 3945TBMJ].
5. Deborah A. Widiss, Gilbert Redux: The Interaction of the Pregnancy
Discrimination Act and the Amended Americans with Disabilities Act, 46 U.C. DAVIS L.
REV. 961, 1002 (2013) (“Courts have also failed to develop the robust understanding of
“‘equal opportunity’—that is, the right of ‘women, as well as men, to have families without
losing their jobs’—endorsed in Cal Fed as a justification for providing pregnancy-specific
benefits.”).
6. Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1663
(2008) (“In fact, FDLs [fetal drug laws] do little to tell us about harms to fetuses as these
laws exempt from prosecution a host of behaviors that negatively impact pregnancies and
cause miscarriages, such as smoking, second-hand smoke, diabetes, obesity, depression, and
hypertension. Indeed, a good number of FDLs have exemptions for legal abortions so that
they may remain consistent with Roe v. Wade.”).
7. Doretta Massardo McGinnis, Prosecution of Mothers of Drug-Exposed Babies:
Constitutional and Criminal Theory, 139 U. PENN. L. REV. 505, 511-13 (1990); see generally
Barry M Lester, Lynne Andreozzi, & Lindsey Appiah, Substance Use During Pregnancy:
Time for Policy to Catch Up with Research, 1 HARM REDUCTION J. 5 (2004),
https://doi.org/10.1186/1477-7517-1-5 [https:// perma.cc/8JFK-QYE3] (“We have Supreme
Court rulings that define drug use as a mental problem, we have modern evidence that
treatment is effective and that there is no reason to consider drug use as different than any
other mental/medical problem; there are treatment programs shown to be effective with drugusing mothers; and there are treatments with the programs involving the courts. We have
identified all other barriers, yet why has policy not changed? Is it because we are still angry
and want to punish these mothers? That we will not forgive them for using drugs when they
are pregnant?”).
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expanding support for new mothers, implicitly acknowledging
the social and medical importance of the “fourth trimester.” 8
According to the essentialist argument, pregnancy is
reduced, under the law, to “biological and physiological facets,
obscuring the important ways in which society and culture shape
the meaning of pregnancy and structure our experience of it.” 9
Equality-promotion statutes like the Pregnancy Discrimination
Act and the Family Medical Leave Act (FMLA) codify this
essentialism. 10 These statutes impose specific burdens that are
measured and implemented, such as accommodations employers
must provide for pregnant employees or appropriate windows for
family medical leave, whatever the additional costs pregnancy
might impose on a woman, her co-parents or caregivers (if any),
and/or family. 11 As a result, new mothers are left to shoulder a
burden related to reproduction heavier than that for men. 12 To the
extent these scholars have explored the relationship between
medical decisions made by pregnant women, they have done so
largely around issues like reproductive choice, the constraints of
the “code of perfect pregnancy,” and the disparate treatment the
law accords specific decisions made by women during
pregnancy. 13 The process by which medical information is
generated, filtered, and ultimately communicated to pregnant
women has received far less scrutiny. 14
8. Jill Cohen, The Fourth Trimester, 61 MIDWIFERY TODAY 26 (2002); Melinda
Wenner Moyer, If Trump Keeps His Promise on Paid Family Leave, Will Working Women
Feel They Can Take It?, SCI. AM. (Jan. 20, 2017), https:// www. scientificamerican.com
/article/if-trump-keeps-his-promise-on-paid-family-leave-will-working-women-feel-theycan-take-it/ [https://perma.cc/Y3BR-SH5L]; Megan A. Sholar, Donald Trump and Hillary
Clinton Both Support Paid Family Leave. That’s a Breakthrough., WASH. POST (Sept. 22,
2016), https://www.washingtonpost.com/ news/ monkey-cage/ wp/ 2016/ 09/ 22/ donaldtrump-and-hillary-clinton-both-support-paid-family-leave-thats-a-breakthrough/ ?utm_term
=.baff3914546c [https://perma.cc/ S272-BH8G].
9. Saru M. Matambanadzo, Reconstructing Pregnancy, 69 SMU L. REV. 187, 190
(2016).
10. Deborah Dinner, The Costs of Reproduction: History and the Legal Construction
of Sex Equality, 46 HARV. C.R.-C.L. L. REV. 415, 422 (2011) (“The PDA and the FMLA
both prohibit sex-role stereotyping and impose cost-sharing mandates on employers.”).
11. Id.
12. Id.
13. See generally Lisa C. Ikemoto, The Code of Perfect Pregnancy: At the Intersection
of the Ideology of Motherhood, the Practice of Defaulting to Science, and the Interventionist
Mindset of Law, 53 OHIO ST. L.J. 1205 (1992).
14. It is worth noting here that this article is limited to legislative and regulatory efforts
aimed at pregnancy as an intended condition. An entirely separate conversation is relevant
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This Essay situates a crucial component of the public health
response to Zika—the effort to develop a safe and effective
vaccine—within this broader literature. It does so in an effort to
highlight the need to revisit the relationship between law and
pregnancy—not only in the areas legal scholars have prioritized
so far, but also in the context of routine and emergency maternal
health, which has heretofore been largely assumed to be governed
by straightforward norms and practices based on medical
evidence and physician ethics. 15 In fact, whereas the current
literature tends to assume or explicitly assert that the relationship
between law and pregnancy is most troubled in the contexts of
reproductive choice, the workplace, or criminal prosecution—i.e.
predictable events and moments that may be assessed at any given
time—it has paid far less attention to emergency contexts like
H1N1, Ebola, or Zika, each of which uniquely affects or affected
pregnant women. 16 In so doing, the literature suggests that social
constructions regulating pregnancy in the workplace or the
prosecutor’s office also regulate the deliberations of public health
officials, physicians, and the medical advice communicated from
them.
Examining the approach adopted by health and medical
regulatory authorities in the U.S. (and mimicked by competent
national regulatory authorities elsewhere) toward pregnant
women in public health emergencies, this Essay argues that
medical research and therapeutic availability are structured so as
to minimize accessibility to pregnant women, even where
evidence suggests—as it did with Ebola and does with Zika—that
to legislative efforts to filter and shape medical information so as to deter abortion. See, e.g.,
Sandhya Somashekhar, Ohio Governor Vetoes ‘Heartbeat Bill’ But Signs Another Abortion
Restriction into Law, WASH. POST., Dec. 13, 2016, https://www.washingtonpost.com
/news/post-nation/wp/ 2016/12/13/ohio-governor-vetoes-heartbeat-bill-but-signs-into-lawanother-abortion-restriction/?utm_term=.3939ee570b8a [https://perma.cc/TPC5-HTQX].
15. Margaret Olivia Little et al., Ethics and Research with Pregnant Women: Lessons
from HIV/AIDS, in 3 CLINICAL RESEARCH INVOLVING PREGNANT WOMEN 227, 237-39
(2016).
16. Kate Greenwood, The Mysteries of Pregnancy: The Role of Law in Solving the
Problem of Unknown But Knowable Maternal-Fetal Medication Risk, 79 U. CIN. L. REV.
267, 268 (2011) (identifying unique risks H1N1 posed to pregnant women); see generally
Annick Antierens, Ethical Challenges in the Development and Deployment of Medical
Therapies and Vaccines in the Context of Public Health Emergencies, in GLOBAL
MANAGEMENT OF INFECTIOUS DISEASE AFTER EBOLA 207, 215 (Sam F. Halabi, Lawrence
O. Gostin & Jeffrey S. Crowley eds., 2017) [hereinafter GLOBAL MANAGEMENT]
(identifying unique risks Ebola posed to pregnant women and their fetuses).
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accessibility for pregnant women needs to be prioritized. Under
this approach, the U.S. Food and Drug Administration (FDA),
which normally must approve medicines and vaccines intended
for specific populations, effectively allocates maternal treatment
and immunization regulation to the Centers for Disease Control
and Prevention (CDC)’ Advisory Committee on Immunization
Practices, the World Health Organization’s strategic advisory
group of experts on immunization, and other national
immunization technical advisory groups. 17
Where those
organizations recommend immunization of pregnant women, the
FDA does not consider the use inconsistent with the product’s
authorized uses or “off-label,” even if there are never doubleblind, placebo controlled trials supporting safety and efficacy
(regardless of whether there are healthy and willing volunteers)—
and trials are rarely designed that seek pregnant participants. 18
While this Essay has as its principal aim the expansion and
catalysis of an important element of the debate now underway in
the law, it also outlines the adverse consequences resulting from
the existing regulatory framework for pregnancy-specific
vaccines (“maternal vaccines”) and foreshadows changes that
will not only be necessary to address future public health
emergencies that threaten pregnant women and their unborn
children, but will also unlock the future of vaccine preventable
deaths. 19 As the world moves toward universal coverage of
17. Richard H. Beigi et al., Research on Vaccines and Antimicrobials During
Pregnancy: Challenges and Opportunities, 31 VACCINE 4261, 4261—63 (2013),
http://www.sciencedirect.com /science /article /pii/ S0264410X13006622 [https://perma
.cc/S5G3-9ZLK].
18. Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831,
30,840–41 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt. 201) (“Therefore, human
data concerning a drug’s effect(s) on pregnant women and their offspring almost never come
from controlled clinical trials. . . . Sources that may contribute to an evaluation of whether a
drug increases the risk of developmental abnormalities include pregnancy exposure
registries, cohort studies, case-control studies, case series, and case reports.”); Jeffery N.
Roberts & Marion F. Gruber, Regulatory Considerations in the Clinical Development of
Vaccines Indicated for Use During Pregnancy, 33 VACCINE 966, 967 (2015),
http://www.sciencedirect.com/
science/
article/
pii/S0264410X1401723X
[https://perma.cc/FSK3-SPZ7].
19. A “maternal” vaccine may designate an immunization administered before, during,
or after pregnancy and the use is not consistent in the literature. See generally Stanley A.
Gall, A Maternal Immunization Program (MIP): Developing a Schedule and Platform for
Routine Immunization During Pregnancy, 29 VACCINE 9411, 9411—13 (2011),
http://www.sciencedirect.com
/science
/article
/pii
/S0264410X
11017634
[https://perma.cc/G3SC-ZM45]. In this Essay, a “maternal” vaccine refers to one
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childhood immunizations, the future of infant health will turn to
immunizations delivered during pregnancy that impart
protections unavailable after birth. 20 This Essay encourages a
new national and international dialogue about maternal and infant
health, and addresses the norms that now characterize biomedical
innovation and corresponding regulatory approaches to
pregnancy.
Part II of this Essay analyzes the recent trend among scholars
to characterize the “essentialist” view of pregnancy legal regimes,
ranging from criminal law to workplace discrimination, adoption,
and the effects of essentialism on women generally and pregnant
women specifically. It then demonstrates that this scholarship has
tended to explicitly assert or implicitly suggest that there is
nevertheless a zone, occurring within the provider-patient
relationship, where the law is less distorted and medical evidence
and physician good faith prevail, even if imperfectly so. Part III
tests this assumption in the literature by analyzing the regulatory
complexities surrounding the licensing of vaccines intended for
pregnancy—including why pregnant women are excluded from
clinical trials, the relationship between product labeling and
vaccine hesitancy among pregnant women, and recent statutory
and regulatory changes aimed at facilitating pregnant women’s
access to essential medicines and vaccines. It concludes that the
administered or intended to be administered to a woman known to be pregnant between
conception and the end of the pregnancy. See, e.g., Maternal Vaccines: Part of a Healthy
Pregnancy, CTRS. FOR DISEASE CONTROL & PREVENTION (Aug. 5, 2016),
https://www.cdc.gov/vaccines/pregnancy/pregnant-women/ [https://perma.cc/474L-HDL9].
20. WORLD HEALTH ORG. ET AL., STATE OF THE WORLD’S VACCINES AND
IMMUNIZATION 75 (3d ed. 2009), http://apps.who.int/iris/bitstream/10665/44169/
1/9789241563864_eng.pdf [https://perma.cc/Q7B7-ZM8G] (“First came the vaccines: by
the early 1970s, vaccines against about 20 diseases had become available, and in most
countries were being used for high-risk population groups (travellers, the military, and so
on), or for occasional mass campaigns, but not routinely in a systematic organized manner.
Then, starting in the mid-1970s, came the [WHO Expanded Programme on Immunization]—
set up to establish and coordinate, on a global scale, the systematic use of vaccines by
national immunization programmes and thereby to protect as many children as possible in
the world against six infectious diseases (diphtheria, tetanus, pertussis, measles, polio, and
tuberculosis). In the mid-1980s, came the evidence that these immunization programmes
could, in a matter of a few years, protect millions of children from disease and death. By the
early 1990s, the drive for universal child immunization (UCI) launched by UNICEF, WHO,
and other partners, had helped raise immunization coverage to a global average of about
80%.”); Seth Berkley, Global Vaccine Access as a Critical Intervention to Fight Infectious
Disease, Antibiotic Resistance, and Poverty, in GLOBAL MANAGEMENT, supra note 16, at
179, 179-81 (noting progress toward universal childhood immunization).
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essentialist approach identified in other legal fields is applicable
to maternal immunizations in both the routine and emergency
contexts; that, as a result, pregnant women’s access to lifesaving
vaccines is thwarted, and development of ethical approaches to
pregnancy-related research is stymied; and that, as with other
legal fields, pregnant women are ultimately disadvantaged
relative to other populations.

II. PREGNANCY AND THE LAW: A REEVALUATION
As the 40th anniversary of the Pregnancy Discrimination Act
and the 25th anniversary of the Family Medical Leave Act
approach (as well as the 30th anniversary of the largest expansion
of prenatal care to low-income pregnant women through
Medicaid), 21 legal scholars have undertaken a comprehensive
review of multiple legal regimes aimed at promoting equality
between pregnant women and other workers, criticizing aspects
of the law that unfairly subject pregnant women to prosecution, 22
and evaluating laws aimed at supporting pregnancy. 23
Contemporaneously, a growing body of medical and public health
literature suggests the benefits of providing better financial and
other forms of support to women after the birth of children, in
addition to the long-known benefits of prenatal care. 24 The issue
21. Marilyn Rymer Ellwood & Genevieve Kenney, Medicaid and Pregnant Women:
Who is Being Enrolled and When, HEALTH CARE FIN. REV., Winter 1995, at 7 (“During the
late 1980s, Congress focused heavily on expanding Medicaid eligibility at the State level for
low-income pregnant women.”).
22. Deborah L. Brake & Joanna L. Grossman, Unprotected Sex: The Pregnancy
Discrimination Act at 35, 20 DUKE J. GENDER L. & POL’Y 67, 67-68 (2013); Saru
Matambanadzo, The Fourth Trimester, 48 U. MICH. J.L. REFORM 117, 121 (2014),
http://repository.law.umich.edu/ cgi/ viewcontent.cgi? article= 1121&context=mjlr
[https://perma.cc/9DX4-SVUV] (reviewing this scholarly undertaking).
23. Candace Marie Reder, Framing Preglimony: Exploring the Implications of
Pregnancy Support Models Through Family Law Values, 20 DUKE J. GENDER L. & POL’Y
325, 327 (2013) (analyzing historical trends in American law supporting pregnancy and
concluding that “the eventual implementation of a pregnancy support scheme seem[s]
inevitable”).
24. See generally Greg R. Alexander et al., Source of Bias in Prenatal Care Utilization
Indices: Implications for Evaluating the Medicaid Expansion, 81 AM. J. PUB. HEALTH 1013
(1991), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1405696/ [https://perma.cc/N7UY99HK]; Pinka Chatterji & Sara Markowitz, Family Leave After Childbirth and the Mental
Health of New Mothers, 15 J. MENTAL HEALTH POL’Y & ECON. 61 (2012),
http://www.icmpe.org/test1/docs/15-061_text.pdf [https://perma.cc/2VEK-N9UL]; Ann
D. Colle & Michael Grossman, Determinants of Pediatric Care Utilization, 13 J. HUM. RES.
115 (1978), http://www.nber.org/ papers/w0240.pdf [https://perma.cc/J9HB-F8QN]; Mark
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of better laws for pregnant women became a rare point of
agreement between the two major presidential candidates in the
2016 U.S. elections. 25
At the core of this effort is the promotion of a more
comprehensive view of pregnancy, of the costs it imposes, and
how those costs are distributed over a society that, generally, aims
to promote not only equality between men and women but healthy
generations to succeed them. 26 The law, according to these
scholars, takes an “essentialist” view of pregnancy,
conceptualizing it “for much of gestation as an individual process
that need not involve partners or other family members.
Pregnancy is individual for the majority of [its] duration” because
of a social choice to make it so. 27 This process is fundamentally
biological and medical: it involves mainly gestation and perhaps
gastrointestinal symptoms, fluctuation in blood pressure, chronic
pain, nausea, changes in body size, and distribution of body
mass. 28 That it involves a great deal more is, effectively, ignored,
at least insofar as the law is concerned. 29
Daku, Amy Raub & Jody Heymann, Maternal Leave Policies and Vaccination Coverage: A
Global Analysis, 74 SOC. SCI. & MED. 120 (2012), http:// www. sciencedirect.com/ science/
article/ pii/ S0277953611006563 [https://perma.cc/HV59-BHQ4]; Mary Kathryn Hamman,
Making Time for Well-Baby Care: The Role of Maternal Employment, 15 MATERNAL &
CHILD HEALTH J. 1029 (2011), https://link.springer.com/article/ 10.1007/s10995-010-06579 [https://perma.cc/8KG6-Q9ZF]; R.S. McDuffie, Jr. et al., Effect of Frequency of Prenatal
Care Visits on Perinatal Outcome Among Low-Risk Women: A Randomized Controlled
Trial, 275 JAMA 847 (1996); Pat McGovern et al., Postpartum Health of Employed Mothers
5
Weeks
After
Childbirth, 4
ANNALS
FAM.
MED.
159
(2006),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1467019/
pdf/0040159.pdf
[https://perma.cc/Y557-5HFL]; Claire Cain Miller, The Economic Benefits of Paid Parental
Leave, N.Y. TIMES (Jan. 30, 2015), https://www.nytimes .com/2015/02/01/upshot/theeconomic-benefits-of-paid-parental-leave.html?_r=0 [https://perma.cc/6755-UDXL].
25. Paid Family and Medical Leave, HILLARY FOR AM., https:// www. hillaryclinton
.com/ issues /paid-leave / [https://perma.cc/BTS8-9ZNP] (“As president, Hillary will:
Guarantee [sic] up to 12 weeks of paid family and medical leave to care for a new child or a
seriously ill family member, and up to 12 weeks of medical leave to recover from a serious
illness or injury of their own.”); Richard Pérez-Peña, How the Trump and Clinton Child Care
Plans Stack Up, N.Y. TIMES (Sept. 14, 2016), https://nyti.ms/2cPbody
[https://perma.cc/8X9S-RE82 ] (“[Trump] proposed requiring employers to give six weeks
of maternity leave . . . .”).
26. Muller v. Oregon, 208 U.S. 412, 421 (1908).
27. See Matambanadzo, supra note 9, at 252.
28. Id. at 256.
29. See Matambanadzo, supra note 22, at 129; see also Erma Jean Lawson & Shireen
Rajaram, A Transformed Pregnancy: The Psychosocial Consequences of Gestational
Diabetes, 16 SOC. HEALTH & ILLNESS 536, 537 (1994) (“Researchers have focused
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This essentialism distorts laws aimed at promoting equality
for pregnant women, subjects them to arbitrary legal
disadvantages, and unfairly distributes the costs of reproduction
over all of the social actors who benefit from healthy mothers and
babies. 30 In the context of pregnancy discrimination, Saru
Matambanadzo has argued that this essentialism explains why
Congress has failed to pass legislation extending discrimination
protection to reproductive choice, breastfeeding, fertility
treatments, or even infant care. 31 Even within the primary
antidiscrimination statute meant to protect pregnant women—the
Pregnancy Discrimination Act—“many courts currently reduce
pregnancy discrimination to gestation-based discrimination,
obscuring not only social and cultural aspects of pregnancy
discrimination, but also a host of medical conditions that are
explicitly related to pregnancy and childbirth . . . .” 32 Deborah
Dinner has persuasively argued that the “design of workplace
structures” has incorporated this essentialism “in a manner that
disproportionately burdens women” so as to conserve an obsolete
model of family-wage earning under which men are breadwinners
and women are caregivers. 33
While the Pregnancy Discrimination Act was intended to
level the playing field between pregnant and non-pregnant
workers, 34 the Family Medical Leave Act (though phrased in sex-

considerable attention on the psychological transitions of a ‘normal’ pregnancy. Sociological
models have reported that the medicalisation of reproduction, the social subordination of
women, and the social construction of motherhood influence the psychological
disequilibrium of pregnancy”); see generally Claudia Barcellos Rezende, The Experience of
Pregnancy: Subjectivity and Social Relations, 8 VIBRANT: BRAZ. J. ANTHROPOLOGY 529
(2011),
http://www.scielo.br/
scielo.php?
script=sci_arttext&pid=S180943412011000200026 [https://perma.cc/4ZJE -29DF].
30. The year 2018 is also the 30th anniversary of the effective date of the substantial
Medicaid expansion for pregnant women under the federal Omnibus Budget Reconciliation
Act. States rapidly adopted expansions for low-income pregnant women under the law.
Deborah A. Calloway, Accommodating Pregnancy in the Workplace, 25 STETSON L. REV.
1, 19-21 (1995) (detailing adverse social outcomes from not supporting pregnant women);
Ian T. Hill, Improving State Medicaid Programs for Pregnant Women and Children,
HEALTHCARE FIN. REV., Dec. 1990, at 76.
31. See Matambanadzo, supra note 9, at 257.
32. Id. at 259; see generally Widiss, supra note 5.
33. See Dinner, supra note 10, at 487.
34. Pregnancy Discrimination Act of 1978, 42 U.S.C. § 2000e(k) (2006); Joanna L.
Grossman, Pregnancy, Work, and the Promise of Equal Citizenship, 98 GEO. L.J. 567, 60205 (2010); Joanna L. Grossman, Hard Labor: New Pregnancy Discrimination Guidance
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neutral language), was aimed at protecting women generally and
pregnant women specifically. 35 The FMLA allows women to
take “serious health condition” leave for needed prenatal care or
if the pregnancy causes inability to work, or as needed for
childbirth, recovery, and to care for a newborn child. 36 Because
of the FMLA’s notice requirements, limited benefits, and total 12week protection from adverse employment consequences, it has
had a modest impact in improving outcomes for women and
children. 37 The essentialist critique explains, in part, this limited
effect. Because the entire statutory leave is 12 weeks, women
who must take leave for gestation-related conditions lose time
that may be taken after birth. 38
This essentialism not only shapes and distorts law ostensibly
aimed at protecting pregnant women from discrimination, but
results in the drafting of criminal statutes that selectively favor
some conduct during pregnancy but not other conduct that might
be just as harmful to a pregnant woman or her fetus. Michele
Goodwin, for example, argues that fetal drug laws, which subject
women to prosecution for conduct that harms a fetus, substitute
medical evidence as to fetal harm with notions of “birthing the
right way” based on conceptions related to essentialist ideas. 39
from the EEOC, VERDICT (July 22, 2014), http://scholarlycommons.law.hofstra.edu/
faculty_scholarship/355 [https://perma.cc/9YSY-5YXE].
35. 29 U.S.C. § 2601 (2012); Joanna L. Grossman & Gillian L. Thomas, Making
Pregnancy Work: Overcoming the Pregnancy Discrimination Act’s Capacity-Based Model,
21 YALE J.L. & FEMINISM 15, 25 (2009).
36. 29 U.S.C. § 2612(a) (2012).
37. Rafael Gely & Timothy D. Chandler, Maternity Leave Under the FMLA: An
Analysis of the Litigation Experience, 15 WASH. U. J.L. & POL’Y 143, 151 (2004)
(“However, the data also suggests that the impact has been rather modest, particularly with
regard to employees that need to take leave due to birth or adoption.”); Michael Selmi, The
Limited Vision of the Family and Medical Leave Act, 44 VILL. L. REV. 395, 396 (1999)
(arguing that “the FMLA was primarily a symbolic act, which afforded no significant
assistance to working women, or men, and has perhaps retarded progress on the family leave
front more than it has plausibly helped”); see generally Richard Bales & Sarah Nefzger,
Employer Notice Requirements Under the Family and Medical Leave Act, 67 MO. L. REV.
883 (2002) (discussing notice provisions).
38. Lawrence M. Berger, Jennifer Hill & Jane Waldfogel, Maternity Leave, Early
Maternal Employment and Child Health and Development in the US, ECON. J., Feb. 2005, at
F31-32.
39. Michele Goodwin, Fetal Protection Laws: Moral Panic and the New
Constitutional Battlefront, 102 CAL. L. REV. 781, 786 (2014) (“[L]egislative fetal protection
efforts are on the rise, driving the creation, enactment, and enforcement of statutes
authorizing criminal intervention in women’s pregnancies. These statutes dramatically
exceed prior limits, extending beyond penalizing poor African American pregnant women
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For pregnant women in prison, medical care and alternatives to
prison routines are similarly structured around gestation-focused
conceptions of how women experience pregnancy. 40
Yet, for the reach and strength of these arguments
challenging the legal environment for pregnant women, the zone
that surrounds the public health approach to pregnant women
generally and the physician-patient relationship specifically has
received far less scrutiny from legal scholars. So, for example,
Professor Matambanadzo contrasts federal judges’ knowledge
(and the resulting narrowing interpretation of the Pregnancy
Discrimination Act) with the “sophisticated medical and
scientific knowledge that many doctors, maternal nurses, and
midwives possess.” 41 Deborah Widiss identifies dozens of
Pregnancy Discrimination Act cases in which women requested
accommodations under doctors’ orders and how courts failed to
give the physician-patient relationship the deference it
deserved. 42 Even within the quite large literature on “maternalfetal” conflict, which as Michelle Oberman points out, may be
rearticulated as a “maternal-physician” conflict, the arguments
largely revolve around points where evidence and advice
diverge—like cesarean births—as opposed to routine maternal
care or recommendations made in the course of public health
emergencies. 43
for illicit drug use, particularly crystallized cocaine (crack). Contemporary fetal
protectionism includes sanctioning women for refusing cesarean sections, forcibly confining
them to bed rest, and instigating prosecutions for otherwise legal conduct.”); Goodwin, supra
note 6, at 1661-62.
40. Deborah Ahrens, Incarcerated Childbirth and Broader “Birth Control”:
Autonomy, Regulation, and the State, 80 MO. L. REV. 1, 4 (2015) (“In the past decade, there
have been a number of academic articles and interest-group reports that document the
problems that women who are pregnant and birthing face while incarcerated, and those
articles and reports have focused in particular on the practice of shackling women who are
pregnant during transportation, court appearances, and, most sympathetically, labor.”);
Pricilla A. Ocen, Punishing Pregnancy: Race, Incarceration, and the Shackling of Pregnant
Prisoners, 100 CAL. L. REV. 1239, 1310 (2012); Kelly Parker, Pregnant Women Inmates:
Evaluating Their Rights and Identifying Opportunities for Improvements in Their Treatment,
19 J.L. & HEALTH 259, 261-64 (2004).
41. See Matambanadzo, supra note 9, at 190.
42. See Widiss, supra note 5, at 1018-25.
43. Michelle Oberman, Mothers and Doctors’ Orders: Unmasking the Doctor’s
Fiduciary Role in Maternal-Fetal Conflicts, 94 NW. U. L. REV. 451, 473-74 (2000). For
literature regarding the maternal-fetal conflict after Roe v. Wade more generally see Janet
Gallagher, Prenatal Invasions and Interventions: What’s Wrong with Fetal Rights, 10 HARV.
WOMEN’S L.J. 9, 51-53 (1987); see generally Susan Markens et al., Feeding the Fetus: On
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Recent public health emergencies provide substantial
reasons to question these assertions and oversights. The
approaching anniversaries of these laws have been accompanied
by major public health emergencies that uniquely affected
pregnant women and their unborn children. Pregnant women
infected with H1N1 were more likely to be hospitalized and die
from the virus. 44 All reported pregnancies in Ebola-infected
women ended in “spontaneous miscarriage, stillbirth or neonatal
death.” 45 The Zika virus, of course, uniquely attacks fetal tissue,
resulting in a wide range of serious birth defects that cause death
and permanent disability. 46 These health emergencies brought
new urgency and focus to the relationship between pregnant
women and vaccines—and, as argued herein, exposed how
essentialist critiques applied to the workplace or in the criminal
context have as much or more force in the advice given to women
about both routine and emergency vaccinations.

III. THE SHADOW REGULATORY REGIME FOR
EMERGENCY AND ROUTINE MATERNAL
VACCINES

Interrogating the Notion of Maternal-Fetal Conflict, 23 FEMINIST STUD. 351 (1997);
Lawrence J. Nelson, Legal Dimensions of Maternal-Fetal Conflict, 35 CLINICAL
OBSTETRICS & GYNECOLOGY 738 (1992); Matthew C. Reid & Grant Gillett, The Case of
Medea—A View of Fetal-Maternal Conflict, 23 J. MED. ETHICS 19 (1997).
44. Sonja A. Rasmussen, Denise J. Jamieson & Joseph S. Bresee, Pandemic Influenza
and Pregnant Women, 14 EMERGING INFECTIOUS DISEASES 95, 95 (2008) (“Pregnant
women are at high risk for severe complications of influenza during interpandemic periods
and previous pandemics. In addition, some studies suggest an increased risk for adverse
outcomes among infants born to mothers infected with influenza during pregnancy.”); Sonja
A. Rasmussen, Denise J. Jamieson & Timothy M. Uyeki, Effects of Influenza on Pregnant
Women and Infants, 207 AM. J. OBSTETRICS & GYNECOLOGY S3, S3 (2012),
http://www.ajog.org/article/S0002-9378(12)00722-3/pdf [https://perma.cc/9GY8-H6NJ].
45. Benjamin O. Black et al., Ebola Viral Disease and Pregnancy, OBSTETRIC MED.,
Sept.
2015,
at
108,
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582839/
pdf/10.1177_1753495X15597354.pdf [https://perma.cc/5YJ8-EXS6].
46. Microcephaly and Other Birth Defects, CTRS. FOR DISEASE CONTROL &
PREVENTION,
https://www.cdc.gov/zika/healtheffects/birth_defects.html
[https://
perma.cc/G7NX-B6L4] (“Congenital Zika syndrome is described by the following five
features: [s]evere microcephaly where the skull has partially collapsed[;] [d]ecreased brain
tissue with a specific pattern of brain damage[;] [d]amage to the back of the eye[;] [j]oints
with limited range of motion, such as clubfoot[;] [and t]oo much muscle tone restricting body
movement soon after birth[.]”); see generally Fernanda R. Cugola et al., The Brazilian Zika
Virus Strain Causes Birth Defects in Experimental Models, 534 NATURE 267 (2016).
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There has arguably never been as strong a case for the
development of a pregnancy-specific (“maternal”) vaccine as
there is for Zika. 47 Discovered in Uganda in 1947, the Aedes
mosquito-borne virus has long been associated with relatively
mild symptoms like “fever, muscle aches, eye pain, prostration,
and maculopapular rash.” 48 In 2015, however, a cluster of
microcephaly cases—a condition that results in a smaller than
normal head size and sometimes severe disability—was
discovered in Brazil and quickly associated with the Aedes and
the Zika virus it carried. 49 Not only had the virus evolved to
attack fetal tissue, but it also demonstrated a potential to infect
populations at high rates. 50 A 2009 study based on antibody
surveys estimated that an “astonishing” 73% of the population
had become infected with Zika virus during an outbreak in Yap,
an island group in the Western Pacific. 51 Over 60% of the United
States’ population lives in areas conducive to seasonal Zika
transmission, and there are even some that live in areas where
yearlong Zika transmission is possible. 52 During 2016, the CDC
47. Zika Epidemic Highlights Need for Priority Vaccine Research and Guidelines for
Pregnant Women, EMORY NEWS CTR. (Feb. 24, 2016), http://news.emory.edu /stories
/2016/02/zika_highlights_need/ [https://perma.cc/ZN W6-74R9].
48. Anthony S. Fauci & David M. Morens, Zika Virus in the Americas—Yet Another
Arbovirus Threat, 374 NEW ENG. J. MED. 601, 601-02 (2016); see also Andrew Green,
Uganda Discovered the Zika Virus. And the Solution For It, FOREIGN POL’Y (Feb. 10, 2016),
http://foreignpolicy.com/2016/02/10/uganda-discovered-the-zika-virus-and-the-solutionfor-it/ [https://perma.cc/NSR7-7FK7].
49. Wanderson Kleber de Oliveira et al., Increase in Reported Prevalence of
Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus
Transmission During the First Trimester of Pregnancy—Brazil, 2015, 65 MORBIDITY &
MORTALITY WKLY. REP. 242, 242-44 (2016), https://www.cdc.gov /mmwr/ volumes
/65/wr/mm6509e2.htm [https://perma.cc/N2TM-UVT2]; One Year into the Zika Outbreak:
How an Obscure Disease Became a Global Health Emergency, WORLD HEALTH ORG.,
http://www.who.int /emergencies /zika-virus /articles /one-year-outbreak /en/index3.html
[https://perma.cc/YZQ5-NUVR].
50. Rafael A. Larooca et al., Vaccine Protection Against Zika Virus from Brazil, 536
NATURE 474, 474, 477 (2016), http://www.nature.com /nature /journal / vaap/ ncurrent/ full/
nature18952.html [https://perma.cc/US4A-FD7F].
51. See Mark R. Duffy et al., Zika Virus Outbreak on Yap Island, Federated States of
Micronesia, 360 NEW ENG. J. MED. 2536, 2536, 2539 (2009), www.nejm.org /doi /pdf
/10.1056 /NEJMoa0805715 [https://perma.cc/7FPT-9BQ4]; see also Mary Kay Kindhauser
et al., Zika: The Origin and Spread of a Mosquito-Borne Virus, WORLD HEALTH ORG. (Feb.
9, 2016), http://www.who.int/bulletin/ online_first/16-171082/en/ [https://perma.cc/RZ8H9ZA3].
52. Isaac I. Bogoch et al., Anticipating the International Spread of Zika Virus from
Brazil, 387 LANCET 335, 335-36 (2016), http://www.thelancet.com /journals/ lancet /article
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reported 224 locally-acquired mosquito-borne cases of the Zika
virus, and 4,830 travel-associated cases; as of August 8, 2017,
2,112 pregnant women showed evidence of Zika infection in the
U.S. alone. 53
Yet, not only have medical researchers made clear they will
not enroll pregnant women in trials for Zika vaccine candidates,
but there is, in fact, not a single vaccine specifically licensed for
use by pregnant women in the United States, for either routine or
emergency purposes. 54 Despite the availability of a detailed
channel for review and licensing by the FDA, physicians advise
pregnant women as to recommended vaccinations (both routine
and emergency) through an alternative regulatory regime that
emphasizes the role of national technical advisory groups, but not
double-blind, placebo-controlled clinical trials. The existence of
this alternative regulatory pathway is explained by the same
essentialism that influences other legal regimes: the narrow focus
on gestation as the touchstone characteristic of pregnancy.
While FDA review plays an important role in vaccine
confidence—because vaccines are administered to otherwise
healthy adults and children, a high standard of safety is
expected—the upshot of circumventing the FDA for maternal
vaccines is less access both at the experimental stage and, through
hesitancy, at the patient stage. 55 Perceptions of safety risk, even
mild ones, may exert a disproportionate effect on the willingness

/PIIS0140-6736(16)00080-5/abstract [https://perma.cc/8Y3L-KC9F]; see generally Andrew
J. Monaghan et al., On the Seasonal Occurrence and Abundance of the Zika Virus Vector
Mosquito Aedes Aegypti in the Contiguous United States, PLOS CURRENTS: OUTBREAKS
(Mar. 16, 2016), http://currents.plos.org/outbreaks/ article/on-the-seasonal-occurrence-andabundance-of-the-zika-virus-vector-mosquito-aedes-aegypti-in-the-contiguous-unitedstates/ [https://perma.cc/L8TB-FBCC].
53. 2016 Case Counts in the US, CTRS. FOR DISEASE CONTROL & PREVENTION (May
10, 2017), https:// www.cdc.gov /zika /reporting /2016-case-counts. html [https://perma.cc/
7M3N-BVQX]; Pregnant Women with Any Laboratory Evidence of Possible Zika Virus
Infection in the United States and Territories, CTRS. FOR DISEASE CONTROL & PREVENTION
(Aug. 8, 2017), https://www.cdc.gov/ zika/reporting/ pregwomen- uscases. html
[https://perma.cc/KC8L-3L88].
54. Geeta K. Swamy & R. Phillips Heine, Vaccinations for Pregnant Women, 125
OBSTETRICS & GYNECOLOGY 212, 221 (2015).
55. Saad B. Omer & Sam F. Halabi, Evidence, Strategies, and Challenges for Assuring
Vaccine Availability, Efficacy, and Safety, in GLOBAL MANAGEMENT, supra note 16, at 223,
228.
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of pregnant women to accept vaccinations. 56 The critical role of
trust explains the robust regulatory review to which vaccines are
subjected before licensure as well as the systems in place to search
for rare adverse events that would not be necessary in the context
of approval or acceptance for other kinds of pharmaceuticals.

A. The FDA Approval Process
The FDA’s Center for Biologics Evaluation and Research
(CBER) is responsible for regulating vaccines in the United
States, and its approval facilitates the use of vaccines in countries
that lack regulatory capacity. 57
While vaccine clinical
development follows the same general pathway as drugs and
other biologics, the process in place for maternal vaccines has
never been used. 58
As researchers identify and isolate the relevant pathogen,
they seek to understand, to the greatest extent possible, the
biological mechanism or mechanisms that lead to disease. 59 Most
vaccine candidates are developed using empirical approaches—
historically serial propagation of a pathogen through media that
diminishes pathogenicity or which is killed or dissected after

56. WORLD HEALTH ORG., REPORT OF THE SAGE WORKING GROUP ON VACCINE
HESITANCY 26 (2014), http://www.who.int /immunization /sage /meetings/ 2014 /october
/1_ Report_ WORKING_GROUP_vaccine_hesitancy_final.pdf [https://perma.cc/HG6678EN]; Allison T. Chamberlain et al., Factors Associated with Intention to Receive Influenza
and Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccines During Pregnancy: A
Focus on Vaccine Hesitancy and Perceptions of Disease Severity and Vaccine Safety, PLOS
CURRENTS: OUTBREAKS (Feb. 25, 2015), http://currents.plos.org/outbreaks/article/factorsassociated-with-intention-to-receive-influenza-and-tetanus-diphtheria-and-acellularpertussis-tdap-vaccines-during-pregnancy-a-focus-on-vaccine-hesitancy-and-perceptionsof/ [https://perma .cc/5LJR-VATG].
57. See Vaccine Product Approval Process, FOOD & DRUG ADMIN.,
http://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicensea
pplicationsblaprocess/ucm133096.htm (last accessed Aug. 26, 2017) [https://
perma.cc/92WU-PTEM]; Michael J. Brennan, The US Food and Drug Administration
Provides a Pathway for Licensing Vaccines for Global Diseases, PLOS MED. (Jul. 21, 2009),
http:// journals.plos.org /plosmedicine /article?id= 10.1371/journal.pmed.1000095
[https://perma.cc/S3XD-6A59].
58. 42 U.S.C. § 262(i), (k) (2012); see also FOOD & DRUG ADMIN., CLINICAL
DEVELOPMENT AND REQUIREMENTS FOR LICENSURE OF VACCINES INTENDED FOR USE
DURING PREGNANCY TO PREVENT DISEASE IN THE INFANT 3 (2015) [hereinafter CLINICAL
DEVELOPMENT].
59. PRINCIPLES OF BACTERIAL PATHOGENESIS, at xv (Eduardo A. Groisman ed.,
2001).
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cultivation and used in relatively large doses. 60 More recent
techniques like “reverse vaccinology” start from “genomic
sequences” and, by computer simulation, predict “those antigens
that are most likely to be vaccine candidates.” 61 Vaccine
candidates are then tested in animals after developing models for
immunogenicity and safety.
After satisfactory animal testing, the FDA authorizes the
sponsor to undertake clinical trials on humans. Phase I of these
trials “is designed to assess the safety, immunogenicity, and dose
response of the vaccine in, typically, 20 to 100 healthy
volunteers.” 62 In Phase II, the sample size is increased to several
hundred healthy volunteers and investigators focus on safety as
well as immunogenicity. 63 Phase III vaccine trials enroll up to
thousands of human subjects in order to detect sometimes rare
adverse events. 64 If Phase III trials “confirm safety and
efficacy . . . the vaccine is approved for marketing after internal
review of study data.” 65
In addition to pre-licensure vaccine clinical trials, the FDA
requires a biologics license application, inspection of the
manufacturing facility, presentation of findings to the FDA’s
Vaccines and Related Biological Products Advisory Committee,
and usability testing of product labeling. 66 The ’Vaccines and
Related Biological Products Advisory Committee “reviews and
evaluates data” to determine “safety, effectiveness, and
60. Nicola P. Klein et al., Waning Protection After Fifth Dose of Acellular Pertussis
Vaccine in Children, 367 NEW ENG. J. MED. 1012, 1013 (2012), http://www.
nejm.org/doi/pdf/10.1056/NEJMoa1200850 [https://perma.cc/FA8C-W3B7]; Bo Ma et al.,
Characteristics and Viral Propagation Properties of a New Human Diploid Cell Line,
Walvax-2, and Its Suitability as a Candidate Cell Substrate for Vaccine Production, 11 HUM.
VACCINES & IMMUNOTHERAPEUTICS 998, 1004-05 (2015).
61. Rino Rappuoli, Reverse Vaccinology, a Genome-Based Approach to Vaccine
Development, 19 VACCINE 2688, 2689 (2001).
62. Omer & Halabi, supra note 55, at 225; see also 21 C.F.R. § 312.23(a)(6)(i) (2016).
63. Phase II Trial: About Phases of Clinical Trials, U.S. NAT’L INSTS. HEALTH,
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0022683/ [https://perma.cc/WN6 HHWD2].
64. L. Simonsen et al., More on RotaShield and Intussusception: The Role of Age at
the Time of Vaccination, 192 J. INFECTIOUS DISEASES S36, S37 (2005),
https://academic.oup.com/jid/article-lookup/doi/10.1086/431512 [https://perma.cc/VA 2Z8DRC].
65. See Omer and Halabi, supra note 55, at 226.
66. Vaccine Testing and the Approval Process, CTRS. FOR DISEASE CONTROL &
PREVENTION, http:// www.cdc.gov /vaccines /basics /test-approve.html [https:// perma.cc
/ZE3B-GA65].
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appropriate use of vaccines.” 67 Members and the Chair are
selected by the Commissioner or designee from among
“authorities knowledgeable in the fields of immunology,
molecular
biology,
rDNA,
virology[,]
bacteriology,
epidemiology or biostatistics, vaccine policy, vaccine safety
science, federal immunization activities, vaccine development
including translational and clinical evaluation programs, allergy,
preventive
medicine,
infectious
diseases,
pediatrics,
68
microbiology, and biochemistry.”
The committee reviews
vaccinations as one of the final steps before approval by the
FDA. 69

B. Requirements for Vaccines Intended for Use During
Pregnancy
Under guidelines issued by the FDA, additional
requirements apply to vaccines developed for use during
pregnancy. Animal testing and clinical testing must be specified
to address the potential reproductive risk of the product before
enrolling any pregnant women into clinical trials. 70 Phase I
clinical trials for maternal immunizations begin with nonpregnant women of childbearing age. 71 If results of the proposed
vaccination are positive, studies of the vaccination may be
advanced into early studies of pregnant women classified as lowrisk. 72 If adequate data from Phase I clinical trials of pregnant
women is observed, Phase II may begin to identify a “pilot
evaluation of efficacy.” 73 As with Phase III trials generally, trials
for vaccine candidates intended for use during pregnancy are
required to use a prospective, randomized, blinded, wellcontrolled study, wherein the control arm receives a placebo (or
unrelated vaccine) and the primary endpoint is prevention of

67. Vaccines and Related Biological Products Advisory Committee, FOOD & DRUG
ADMIN., http://www.fda.gov /AdvisoryCommittees /CommitteesMeeting Materials
/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryComm
ittee/default.htm [https://perma.cc/J44K-E98Q].
68. Id.
69. Vaccine Product Approval Process, supra note 57.
70. Roberts & Gruber, supra note 18, at 968.
71. Id.
72. Id.
73. Id.
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clinical disease in a wider population of pregnant women (not
limited to low-risk pregnancies). 74 After clinical development
stages, the vaccination would advance to the licensing
application, where FDA reviewers would assess the information
necessary to make a risk/benefit decision and a recommendation
for the approval of the vaccine. 75
Safety evaluations are incredibly important during each
phase of the clinical trials, but continue after the approval of the
vaccine. 76 It is essential to develop a systematic approach to
classifying adverse events to be able to assess causality when an
adverse event is observed in the clinical trial. 77 Until a vaccine is
given to the general population, all potential adverse reactions
cannot be anticipated. 78 Thus, many vaccines undergo Phase IV
studies once on the market, and strict safety reporting standards
are in place during and after clinical trials. 79 A key criterion
during Phase IV studies is to determine if there is a “reasonable
possibility that the drug (or biologic) caused [an adverse] event
and whether the event (or pattern of events) is unexpected.” 80
During general population use of the vaccination, it may be
necessary to develop a pregnancy registry in order to explore
potential changes and improve the quality and utility of the
vaccination. 81

C. Labeling
Approval of vaccines “also requires . . . adequate product
labeling to allow health care providers to understand the vaccine’s
74. Id.
75. 42 U.S.C. § 262(k) (2012); Vaccine Product Approval Process, supra note 57.
76. See Vaccine Product Approval Process, supra note 57.
77. Roberts & Gruber, supra note 18, at 969; Alberto E. Tozzi et al., Assessment of
Causality of Individual Adverse Events Following Immunization (AEFI): A WHO Tool For
Global Use, 31 VACCINE 5041, 5041-5042 (2013), http://www.sciencedirect.com /science
/article /pii /S0264410X13011997 [https://perma .cc/P7JT-MZL9].
78. See Vaccine Product Approval Process, supra note 57.
79. Id.; see also Geert Leroux-Roels et. al., Vaccine Development, 1 PERSPECTIVES IN
VACCINOLOGY 115, 123 (2011) (“Phase IV surveillance studies, because of the large sample
size involved, are designed to detect very rare adverse events (AEs) that are difficult to pick
up in Phase III studies.”).
80. Roberts & Gruber, supra note 18.
81. Id. at 969; see generally Eileen Wilson et al., Varicella Vaccine Exposure During
Pregnancy: Data from 10 Years of the Pregnancy Registry, 197 J. INFECTIOUS DISEASES
S178 (2008).
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proper use, including its potential benefits and risks, to
communicate with patients and parents, and to safely deliver the
vaccine to the public.” 82 A product’s package insert, also known
as the label, is a critical element of the evaluation of a
vaccination. 83 Vaccine labels must include a section for usage
during pregnancy. 84
Until recently, information on a product insert was
categorized using a letter system under which each letter
represented the relative availability of clinical information.85
Category A pharmaceuticals were those, like folic acid
supplements, where “adequate and well-controlled studies failed
to demonstrate a risk to the fetus in the first trimester of
pregnancy.” 86 Category B pharmaceuticals meant that there were
no adequate and well-controlled studies over human pregnancy,
but animal data was reassuring, while Category C
pharmaceuticals meant that there were no adequate and wellcontrolled human studies and also no positive animal data. 87
Categories D and X conveyed “fetal risk [in] investigational or
marketing . . . studies . . . .” 88
The FDA recently revised the regulations for the
characterization of a drug or biologic as it affects pregnancy and
issued the Pregnancy and Lactation Labeling Rule (“PLLR”). 89
The PLLR changed the labeling rule for biologics (e.g. vaccines)
and pharmaceuticals from categorizing risks into lettered
categories (A, B, C, D, and X) to providing “a narrative summary
of the risks of using [the] drug or biological product during
pregnancy.” 90 The new rule not only requires that this

82. See Vaccine Product Approval Process, supra note 57; see also INST. OF MED.,
THE CHILDREN’S VACCINE INITIATIVE: ACHIEVING THE VISION 164-69 (Violaine S.
Mitchell et al. eds., 1993).
83. See generally 21 C.F.R. §§ 201.56-.57 (2016).
84. Requirements for Pregnancy and Lactation Labeling, 79 Fed. Reg. 72,064, 72,064
(Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201).
85. Marion F. Gruber, The US FDA Pregnancy Lactation and Labeling Rule—
Implications for Maternal Immunization, 33 VACCINE 6499, 6500 (2015).
86. U.S. Dep’t of Health & Human Servs., FDA Pregnancy Categories, CHEMM,
https://chemm.nlm.nih.gov/pregnancycategories.htm [https://perma.cc/ 3MWN-T37U].
87. Id.
88. Id.
89. See generally Requirements for Pregnancy and Lactation Labeling, 79 Fed. Reg.
72,064 (Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201).
90. Gruber, supra note 85, at 6499-500.
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information be adapted to be given in narrative form, but also that
the labeling “include . . . clinical information to help health care
providers make prescribing decisions and counsel women about
the use of drugs during pregnancy . . . .” 91
Even under the new system, the relative risk to pregnant
women considering use is opaque. Consider the product insert
language for a seasonal influenza vaccine still marketed under
Category B:
There are . . . no adequate and well-controlled studies in
pregnant women. Because animal reproduction studies are
not always predictive of human response, this vaccine should
be used during pregnancy only if clearly needed. 92

Or the language for vaccines approved under the new rule:
Available data on Prevnar 13 administered to pregnant
women are [sic] insufficient to inform vaccine-associated
risks in pregnancy. 93

As analyzed below, the continuing difficulty in obtaining
relevant information about vaccines during pregnancy—and the
resulting effect on product labeling—is not the result of a more
comprehensive or objective approach to pregnancy. Rather, it is
a continuation of culturally informed conceptions inseparable
from those influencing regimes dedicated to antidiscrimination,
prosecution, or family support.

D. The Alternative Regulatory Framework for
Maternal Vaccines
Despite FDA guidance on approval of maternal vaccines
through normal channels, the system is unused. Instead, the
approval for maternal vaccines is effectively allocated to national
technical advisory groups like the Advisory Committee on
Immunization Practices (ACIP), a statutory body established to
91. Id.
92. SEQIRUS INC., FLUVIRIN PRODUCT INSERT (2017), http://www.fda.gov /
downloads /BiologicsBloodVaccines /Vaccines /ApprovedProducts /UCM123694.pdf
[https://perma.cc/78V3-SH5H].
93. PFIZER INC., PREVNAR PRODUCT INSERT (2017), http:// www. fda.gov /downloads
/Biologics
Blood
Vaccines
/Vaccines
/ApprovedProducts
/UCM201669.pdf
[https://perma.cc/T34B-H6P2]; see also Guidelines for Vaccinating Pregnant Women, CTRS.
FOR DISEASE CONTROL & PREVENTION (2016), https://www.cdc.gov /vaccines /pregnancy
/hcp/guidelines.html [https://perma.cc/M24N -8ULB].
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“develop recommendations on the use of vaccines in the civilian
population of the United States.” 94 The 15 member steering
committee is appointed by the Secretary of Health and Human
Services after “an application and nomination process,” with 14
of the 15 members being medical experts and one serving as a
consumer representative. 95 The committee reports to the Director
of the CDC. 96
ACIP provides assistance to the CDC “regarding the most
appropriate selection of vaccines and related agents for effective
control of vaccine-preventable diseases.” 97 It also addresses
issues of specific populations such as pregnant and breastfeeding
women. 98
The committee votes on whether to include a new vaccine in
the routine immunization schedule, vaccine use in high risk
groups, and use of vaccines outside the routine
schedules . . . . For each recommended vaccine, the
committee develops written guidance, subject to the
approval of the CDC Director, for administration of FDAlicensed vaccines to children and adults in the US civilian
population, including age for vaccine administration, dose
and frequency of administration, and precautions and
contraindications of vaccine use and information on adverse
events. 99

ACIP uses work groups to investigate data, which the groups
then present to the committee. 100 These work groups “focus on
one vaccine or group of vaccines,” and formulate proposed policy
options by “review[ing] data on morbidity and mortality

94. About ACIP, CTRS. FOR DISEASE CONTROL & PREVENTION (Apr. 15, 2016),
https://www.cdc.gov/vaccines/acip/about.html [https://perma.cc/F46Q-NKXL]; see also 42
U.S.C. § 2l7(a) (2012). .
95. See About ACIP, supra note 94.
96. ACIP: Guidance for Vaccine Recommendations for Pregnant and Breastfeeding
Women, CTRS. FOR DISEASE CONTROL & PREVENTION [hereinafter Vaccine
Recommendations], https://www.cdc.gov/vaccines/acip/committee/guidance/ rec-vacpreg.html [https://perma.cc/6BSY-W4ES].
97. Id.
98. Id.
99. Jean Clare Smith, The Structure, Role, and Procedures of the U.S. Advisory
Committee on Immunization Practices (ACIP), 28S VACCINE A68, A71 (2010),
http://www.sciencedirect.com/science/article/pii/S0264410X10002057
[https://perma.
cc/4T69-G3WW].
100. Id. at A72.
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associated with the disease in the general US population and in
specific risk groups.” 101
While its statutory authority falls within broadly worded
provisions aimed at the role of the CDC in preventing
communicable diseases, ACIP’s authority to recommend
unlicensed vaccines comes from its charter—a document that is
required to be filed under the Federal Advisory Committee Act,
but is otherwise of uncertain legal status. 102 Under ACIP’s
charter, “[g]uidance for use of unlicensed vaccines may be
developed if circumstances warrant. For each vaccine, the
committee advises on population groups and/or circumstances in
which a vaccine or related agent is recommended.” 103 Similarly,
professional organizations like the American Congress of
Obstetricians and Gynecologists, which serve as liaison
organizations to ACIP, develop immunization recommendations
for practitioners that are guided by, but not necessarily
coextensive with, labeling recommendations. 104 The FDA, in
turn, allows these recommendations to substitute for regulatory
review, declaring that “programmatic recommendations (such as
those from WHO, ACIP, and other national immunization
technical advisory groups (NITAGs)) for use during pregnancy
are not inconsistent with FDA labeling.” 105
In March 2008, ACIP approved its Guiding Principles in
Development of ACIP Recommendations for Vaccination During
Pregnancy and Breastfeeding. 106 Previously, ACIP did not
provide any direction to technical advisory groups about creating
policy for vaccination use during pregnancy, 107 so those groups
adopted recommendations that “var[ied] in clarity and underlying

101. Id.
102. CTRS. FOR DISEASE CONTROL & PREVENTION, CHARTER OF THE ADVISORY
COMMITTEE ON IMMUNIZATION PRACTICES 1 (2016), https://www.cdc.gov /vaccines /acip
/committee /acip-charter-2016.pdf [https://perma. cc/K9FM-YTLP].
103. Id. at 2.
104. See, e.g., ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP),
SUMMARY REPORT 6, 10, 23-24 (2012), https://www.cdc.gov/ vaccines /acip /meetings
/downloads/min-archive/min-oct12.pdf [https://perma.cc/WF7 D-YNDD]; Jean Clare Smith
et al., History and Evolution of the Advisory Committee on Immunization Practices—United
States, 1964-2014, 63 MORBIDITY & MORTALITY WKLY. REP. 955, 956 (2014).
105. CLINICAL DEVELOPMENT, supra note 58, at 10.
106. Vaccine Recommendations, supra note 96.
107. Id.
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rationale.” 108 Generally, “[o]bstetrician-gynecologists (ob-gyns)
provide more general medical care to women than either family
practice or internal medicine providers, and” therefore have better
“opportunities to incorporate vaccination into standard clinical
care.” 109
It is through this system that a fairly small number of
vaccinations have been generally accepted for use during
pregnancy. 110 ACIP, for example, recommends that all pregnant
women receive Tdap and seasonal influenza vaccinations, even
though they are not licensed for use during pregnancy. 111 Some
other vaccinations may be recommended based on travel or
specific patient profiles, but, as with influenza and Tdap, none
have been specifically tested in pregnant women. 112
Safety data for maternal immunization is largely gathered
through post-vaccination adverse event monitoring systems,
including pregnancy registries and Phase IV post-immunization
studies. For example, the Vaccine Adverse Event Reporting
System (“VAERS”) collects and analyzes information from
reports of negative side effects that occur during the
administration of U.S. licensed vaccines. 113 This program, cosponsored by the FDA and the CDC, receives around 15,000
reports per year. 114 Because of this program, “researchers detect
new or rare events, identify increases in rates of known side
effects, and enhance understanding of patient risk factors.”115
The Vaccine Safety Datalink (“VSD”), run cooperatively by nine
healthcare organizations and the CDC, “monitor[s] safety of
vaccines and conduct[s] studies about rare and serious adverse
events following immunization . . . based on questions or
108. Id.
109. Swamy & Heine, supra note 54, at 212-13.
110. See id. at 214.
111. Maternal Vaccines: Part of a Healthy Pregnancy, supra note 19; Swamy &
Heine, supra note 54, at 221 (“To date, vaccines in the United States are not specifically
licensed or targeted for use during pregnancy.”).
112. See Swamy & Heine, supra note 54, at 214, 221.
113. Vaccine Adverse Event Reporting System, U.S. DEP’T OF HEALTH & HUM.
SERVS., https://vaers.hhs.gov/index [https://perma.cc/D7ML-J9RX].
114. U.S. FOOD & DRUG ADMIN., REVIEW OF VAERS ANTHRAX VACCINE REPORTS
RECEIVED THROUGH 8/15/05, AND ADVERSE EVENT REPORTS SUBMITTED TO DOCKET NO.
1980N-0208, at 1-2 (2005), http://www.fda.gov/ohrms/ dockets/dockets/80n0208/80n0208-bkg0006-19-Ref-17-VAERS-Vol225.pdf [https:// perma.cc/87ZZ-F66Q].
115. See Halabi & Omer, supra note 55, at 229.
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concerns raised from the medical literature and reports to the
[VAERS].” 116 The results from each data collection program are
“linked with larger databases like the CDC’s Clinical
Immunization Safety Assessment Network (CISA), which
provides a clinical case evaluation service for US healthcare
providers who have vaccine safety questions.” 117

IV. SHADOW REGULATION OF MATERNAL
VACCINES AND THE FUTURE OF MATERNAL AND
INFANT HEALTH
As with analogues in Pregnancy Discrimination Act
jurisprudence and the reach of the Family Medical Leave Act, the
shadow regulatory system for approving vaccines for use during
pregnancy does not reflect the consensus in the medical literature
regarding pregnant women’s participation in clinical trials,
protections for mothers and fetuses codified in federal law, or the
potential value of maternal vaccines for the future of human
health. It reflects a narrow view of pregnancy that focuses on
gestation instead of looking comprehensively at the social and
medical changes that accompany pregnancy.
Although there is substantial evidence to support the use of
vaccines to prevent diseases in mothers and infants, there has
historically been little interest in developing vaccines for use
during pregnancy. 118 Maternal immunization strategies have
been proven to protect infants against neonatal tetanus, and to
protect mothers and infants against influenza and pertussis.119
There have not been any safety concerns identified with regard to
vaccinating women during pregnancy, but regulatory barriers
such as evaluating efficacy and safety pose a limitation. 120

116. Vaccine Safety Datalink (VSD), CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/
[https://perma.cc/QZN3-6U24].
117. Halabi & Omer, supra note 55, at 230.
118. See K. Zaman et al., Effectiveness of Maternal Influenza Immunization in
Mothers and Infants, 359 NEW ENG. J. MED. 1555, 1555-1563 (2008), http://www.ne
jm.org/doi/full/10.1056/NEJMoa0708630#t=article [https://perma.cc/ BV8R-ZZB8]; see
generally Swamy & Heine, supra note 54.
119. Flor M. Munoz, Respiratory Syncytial Virus in Infants: Is Maternal Vaccination
a Realistic Strategy?, 28 CURRENT OPINION INFECTIOUS DISEASES 221, 223 (2015).
120. See Roberts & Gruber, supra note 18, at 966.
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Federal law authorizes the inclusion of pregnant women in
medical research and conditions authorization on several criteria
related to the risk and benefit for both mother and fetus. 121
Despite the care taken within federal regulations to facilitate
participation of pregnant women and implement a meaningful
risk/benefit framework, researchers “reflexively exclude”
pregnant women from clinical research aimed at discovering safe
and effective vaccines. 122 While researchers must justify the
inclusion of pregnant women in a research protocol and specify
what special protections will be implemented, there is no
requirement to justify their exclusion. 123 Since the U.S. National
Institutes of Health (NIH) began to require inclusion of women,
ethnic minorities, and children in research, pregnant women are
the only population for which justification for exclusion does not
need to be given. 124
The reasons for excluding pregnant women are consistent
with the essentialist critique leveled against legal regimes aiming
to protect pregnant women from employment discrimination, to
support them comprehensively during and after pregnancy, and to
selectively promote or punish certain behaviors during
pregnancy. In their path breaking work on barriers to inclusion
of pregnant women in medical research, a joint NIH/FDA team
led by Mary Blehar concluded that:
[R]easons [for excluding pregnant women] include . . . fear
of harm to the fetus and threat of legal liability, concern
about the complicated physiology of pregnant women,
uncertainty whether pregnant women would be willing to
participate, regulations which classify pregnant women as a
‘vulnerable’ population in need of special protections in
research, and vague, ambiguous, and restrictive wording of
121. 45 C.F.R. §§ 46.201-.211 (2016); Vanessa Merton, Impact of Current Federal
Regulations on the Inclusion of Female Subjects in Clinical Studies, in 2 WOMEN AND
HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING WOMEN IN CLINICAL
STUDIES 65, 67-68 (Anna C. Mastroianni, Ruth Faden & Daniel Federman eds., 1994);
COMM. ON THE ETHICAL AND LEGAL ISSUES RELATING TO THE INCLUSION OF WOMEN IN
CLINICAL STUDIES, INST. OF MED., 1 WOMEN AND HEALTH RESEARCH: ETHICAL AND
LEGAL ISSUES OF INCLUDING WOMEN IN CLINICAL STUDIES 142 (Anna C.
Mastroianni, Ruth Faden, & Daniel Federman eds., 1994).
122. Mary C. Blehar et al., Enrolling Pregnant Women: Issues in Clinical Research,
23 WOMEN’S HEALTH ISSUES e39, e40 (2013).
123. Id. at e42.
124. Id.
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regulations, which IRBs in turn interpret conservatively for
pregnant subjects. 125

In their study of industry trials specifically, Kristine Shields and
Anne Lyerly found that only 1% of studies were designed
specifically for pregnant women, and 95% of studies of
conditions that can affect pregnant women excluded pregnant
women from participation. 126 Those studies were Phase IV
studies undertaken as retrospective analyses. 127 As they note: “A
common explanation for the exclusion of pregnant women from
research is the desire to ‘do no harm,’ yet clinical care during
pregnancy often requires the use of medications untested in
pregnancy.” 128 This is true in the context of Zika as well, where
even promising vaccine candidates, if proven safe and effective,
are likely to be administered to women or adolescent girls who
are not pregnant. 129
These exclusions have multiple ramifications for both
maternal and infant health. 130 Because pregnant women are
excluded from vaccine research, the information that
accompanies even recommended vaccines—like seasonal
125. Id. at e40.
126. Kristine E. Shields & Anne Drapkin Lyerly, Exclusion of Pregnant Women From
Industry-Sponsored Clinical Trials, 122 OBSTETRICS & GYNECOLOGY 1077, 1077 (2013).
127. Viraj Suvarna, Phase IV of Drug Development, 1 PERSP. CLINICAL RES. 57, 59
(2010) (“Some of these studies may be retrospective case-control evaluations. These are
done to evaluate rare suspected side effects.”).
128. Shields & Lyerly, supra note 126, at 1080.
129. WORLD HEALTH ORG., WHO/UNICEF ZIKA VIRUS (ZIKV) VACCINE TARGET
PRODUCT PROFILE (TPP): VACCINE TO PROTECT AGAINST CONGENITAL ZIKA SYNDROME
FOR
USE
DURING
AN
EMERGENCY
1,
6
(2017),
http://www.
who.int/immunization/research/development/WHO_UNICEF_Zikavac_TPP_Feb2017.pdf
[https://perma.cc/U93U-S3K6] (“It is not expected that initial products would contain an
indication for use in pregnant women.”); Hilary D. Marston et al., Considerations for
Developing a Zika Virus Vaccine, 375 NEW ENG. J. MED. 1209, 1209-12 (2016) (“Second,
vaccine safety and immunogenicity are generally established in nonpregnant adults before
vaccination of pregnant women is considered—a standard practice that delays vaccine use
in the latter population until some assurances of safety are provided. Hence, it is likely that
vaccinating women of childbearing age (and men in order to prevent sexual transmission)
would be the optimal initial public health strategy. In the longer term, it may be advisable
to vaccinate pediatric populations, well before their first sexual contact. Here, the experience
with rubella is instructive: protection of pregnant women was achieved through broad
vaccination of young children. Adoption of this strategy would depend on the durability of
protection offered by a Zika vaccine.”).
130. Saad B. Omer & Richard H. Beigi, Pregnancy in the Time of Zika: Addressing
Barriers for Developing Vaccines and Other Measures for Pregnant Women, 315 JAMA
1227, 1227-1228 (2016).
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influenza and Tdap—confuses many physicians and depresses
uptake by pregnant women who justifiably question the safety
and efficacy profile of the immunizations. The reflexive
exclusion of pregnant women, without justification, deters the
development of a meaningful risk/benefit framework to apply to
research even where vaccines may do much to address infections,
like RSV and Group B Strep infection that pose serious risks to
infants.

A. The Development of an Ethical Framework and
Risk-Benefit Analysis
Medical researchers and institutional review boards
(“IRBs”—also known as “independent ethics committees”—
assure that appropriate steps are taken to protect the rights
and welfare of humans participating as research subjects) have
largely dodged risk, benefit, and ethics decisions involving
research on pregnant women. 131 Federal law, under “Subpart B”
regulations, requires that risks and benefits be assessed when
undertaking research with pregnant women volunteers, including
the nature and quality of informed consent communications, the
definition of “important biomedical knowledge,” and the research
alternatives, if any, to specific medical interventions. 132 Because
pregnant women are reflexively excluded, often without
explanation, there are confused and competing interpretations of
what these principles might mean. 133

131. Institutional Review Boards Frequently Asked Questions—Information Sheet,
U.S.
FOOD
&
DRUG
ADMIN.,
http://www.fda.gov/RegulatoryInformation/
Guidances/ucm126420.htm [https://perma.cc/4TK8-J8ZY].
132. See 45 C.F.R. §§ 46.203-.204 (2016).
133. See, e.g., IRB Assessment of Risk & Benefit for Research Involving Pregnant
Women and Fetuses (Subpart B), U.C.-IRVINE (Mar. 2013), http://www. research.uci.edu
/compliance/human-research-protections/docs/pregnant-women-fetus-neonates-laminatedsheet.pdf [https://perma.cc/DBC2-SBCR ] (“The risk to the fetus is not greater than minimal
and the purpose of the research is the development of important biomedical knowledge which
cannot be obtained by any other means. Only Mother’s consent is required. NOTE: For DoD
supported research, there are exceptions (e.g., the phrase ‘biomedical knowledge’ in subpart
B shall be replaced with ‘generalizable knowledge’ throughout the subpart). Refer to DoDI
3216.02, version November 8, 2011.” (emphasis omitted)); Janice K. Bush, The Industry
Perspective on the Inclusion of Women in Clinical Trials, 69 ACAD. MED. 708, 712-14
(1994) (detailing conflicting principles with respect to pregnancy and clinical trials).
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“Minimal risk” is a concept that informs the ethical review
of research and is poorly defined in the Subpart B context.134
IRBs often categorize research in pregnancies as “high risk”
without any meaningful development of a decision framework. 135
The lack of a broadly accepted ethical framework and definition
of risk for guiding clinical research during pregnancy has a
limiting effect on both academic and industry-led clinical trials
regarding the Zika virus. 136 The lack of an ethical framework has
a chilling effect on clinical research in pregnancy and could lead
to a similar effect for research of the Zika vaccine because the
virus has implications for pregnant women and women of
reproductive age. 137
Definitions of “risk” and “direct benefit” for both mothers
and fetuses are crucial for this fundamental scientific endeavor. 138
For example, researchers cannot identify appropriate animal
models during development research without a framework under
which their interventions will be assessed later. 139
Public health emergencies magnify the need for these
definitions because they require a real-time assessment of
risks. 140 For example, in 2009, during the H1N1 influenza
pandemic, the risks of disease greatly outweighed the expected
risks from the vaccination of pregnant women, which led to much
needed insight on necessary improvements in research. 141 These
challenges included the need for further articulation of baseline
rates, which would define relevant, expected clinical and
laboratory standards in pregnancy, and the need for accurate
assignment of pregnancy complications. 142 The baseline rate of
outcomes is extremely important when a disease emerges that is
associated with adverse birth outcomes, and development of these
baseline rates could generate large multi-location data sets that
134. See Omer & Beigi, supra note 130, at 1227.
135. Id.
136. Id.
137. Id.
138. See generally Seema Shah et al., How Do Institutional Review Boards Apply the
Federal Risk and Benefit Standards for Pediatric Research?, 291 JAMA 476 (2004), http://
jama. jamanetwork.com /article. aspx ?article id = 198070 &result click =1 [https://perma.cc/
PWS8-ZQLF].
139. See Beigi et al., supra note 17, at 4262.
140. See Omer & Beigi, supra note 130, at 1228.
141. See Beigi et al., supra note 17, at 4262.
142. Id.
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would optimize the evaluation of clinically important outcomes,
such as microcephaly. 143 The Ebola public health emergency
illustrates the dilemma posed by the absence of meaningful
frameworks for ethical review, risk, and benefit. Pregnant women
were excluded from Ebola vaccine trials even though all reported
pregnancies in Ebola infected women ended in spontaneous
miscarriage, stillbirth or neonatal death. 144

B. Toward a More Comprehensive Understanding of
Pregnancy and Its Outcomes
1. Immunity and Early Pregnancy
Most of the current knowledge about vaccine response
comes from studies conducted in the latter part of pregnancy. 145
Pregnancy is a “physiologically dynamic state” and the immune
profile of a pregnant women is responsive to changing levels of
sex hormones throughout different stages of pregnancy. 146 Yet
there is “limited data available from the first and early second
trimester[s]” or from randomized clinical studies, even for
vaccines now recommended by ACIP. 147 For example, while it
is known that pertussis immunization during pregnancy confers
protection on newborns, the “effectiveness and optimal
concentration of maternal antipertussis antibodies in newborns”
is not. 148 High levels of antibodies in the first weeks after birth
likely confer protection and might prevent pertussis or modify
disease severity, but a great deal remains unknown. 149 Similarly,
there are knowledge gaps with respect to the impact of the timing
143. See Omer & Beigi, supra note 130, at 1228.
144. LEONTINE ALKEMA ET AL., TRENDS IN MATERNAL MORTALITY: 1990 TO 2015,
at 26 (2015), http://apps.who.int/iris/bitstream/10665/112682/2/9789241507 226_eng.pdf
[https://perma.cc/75QL-PWCE]; Black et al., supra note 45, at 108; Agence Fr.-Presse, A
New Ebola Vaccine May Be ‘Up to 100 Percent Effective’, PUB. RADIO INT’L (Dec. 24, 2016,
11:15 AM), https:// www. pri.org /stories/ 2016-12-24/ new- ebola- vaccine- may- be- 100percent -effective [https://perma.cc/C35X-3CKA].
145. See Omer & Beigi, supra note 130, at 1227.
146. Id.
147. Id.; see also CLINICAL DEVELOPMENT, supra note 58, at 3.
148. Mark Sawyer et al., Updated Recommendations for Use of Tetanus Toxoid,
Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women,
62 MORBIDITY & MORTALITY WKLY. REP. 131, 131 (2013), https://www.cdc.gov /mmwr
/preview /mmwrhtml /mm6207a4.htm [https://perma.cc/BJ 3S-PKZQ].
149. Id.
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of Tdap during pregnancy on infant pertussis, the safety of
multiple doses of the vaccine in pregnant women, and its overall
effectiveness. 150
With respect to influenza, the medical
community lacks understanding of how different strains of the
influenza virus affect mothers and newborns differently. 151
The Zika emergency highlights the need for better
understanding: the harmful effects of Zika virus infection likely
occur in the early parts of pregnancy, so a Zika vaccine may work
best if administered prior to pregnancy or early in pregnancy. 152
Zika’s link to fetal development highlights the need for pregnant
women and those of reproductive age to be a priority while
moving forward in the developmental stages of this vaccine. 153

2. Understanding Background Events and
Outcomes
Because pregnancy is conceptualized as it is at the IRB
level—a physiological process that should result in the birth of a
healthy baby—there is in fact inadequate understanding of
population level phenomena related to adverse outcomes that
would be necessary to adequately study maternal vaccines. A
major barrier in the approval of pregnancy-specific vaccinations
is the inability to arrive at a “definite etiology for reproductive
effects such as congenital malformations and spontaneous
abortions.” 154 Only one-third of malformed children can be
provided with a diagnosis, and 15% percent of all pregnancies
result in spontaneous abortions. 155 Another challenge is that these
150. Bahaa Abu Raya et al., The Effect of Timing of Maternal Tetanus, Diphtheria,
and Acellular Pertussis (Tdap) Immunization During Pregnancy on Newborn Pertussis
Antibody Levels—A Prospective Study, 32 VACCINE 5787, 5790-92 (2014); see also
CLINICAL DEVELOPMENT, supra note 58, at 9-10; Sawyer et al, supra note 148, at 131-32.
151. Sarah J. Short et al., Maternal Influenza Infection During Pregnancy Impacts
Postnatal Brain Development in the Rhesus Monkey, 67 BIOLOGICAL PSYCHOL 965, 971
(2010).
152. See Omer & Beigi, supra note 130, at 1227.
153. Ian Sample, Zika Virus Vaccine for Animals Brings Hope for Human Protection,
GUARDIAN (June 28, 2016, 11:00 AM), https://www.theguardian.com/ world/ 2016/ jun/28
/zika-virus-vaccine-for-animals-brings-hope-for-human-protection [https://perma.cc/ARE793QZ].
154. Robert L. Brent, Immunization of Pregnant Women: Reproductive, Medical and
Societal Risks, 21 VACCINE 3413, 3415 (2003), http://www.sciencedirect .com/ science/
article/ pii/ S0264410X03003967 [https://perma.cc/U3Z8-QNZA].
155. Id.
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reproductive issues are “clouded by an emotional stigma” that can
lead to partisan positions and produce distracting non-objective
opinions that misinform the public. 156
Indeed, there is not even consensus around standard
definitions for assessing outcomes even if background rates of
malformation and spontaneous abortion might be more
effectively ascertained. 157
For example, a review commissioned by the World Health
Organization highlighted the lack of standard definitions of
outcomes, and standards for measurement of these
outcomes, relevant to evaluation of vaccines in
pregnancy. This lack of standardization poses a challenge
for conduct of clinical trials, generalizability of safety data,
and merging of large safety data sets. This last point is
critical because large multilocation data sets could optimize
the evaluation of rare but clinically important outcomes,
such as microcephaly. 158

Standard definitions are needed for measuring outcomes when
evaluating vaccine safety studies in pregnant women. 159

C. The Physician-Patient Relationship and the Effect
on Maternal and Infant Care
1. Doctor-Patient Communication
While the most immediate effect of these knowledge gaps is
the lack of data on safety and efficacy for drugs and vaccines that
may support maternal and infant health, another area affected is
the communication between physicians and patients. There is
good evidence showing that pregnant women refuse
immunizations based on information in package inserts which
ranges from statements about there being no information to
“safety and effectiveness of [X vaccine] have not been established

156.
157.
Following
(2015).
158.
159.

Id. at 3414-15.
See generally id.; T. Roice Fulton et al., A Systematic Review of Adverse Events
Immunization During Pregnancy and the Newborn Period, 33 VACCINE 6453
Omer & Beigi, supra note 130, at 1228.
See generally Fulton et al., supra note 157.
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in pregnant women . . . .” 160 The inability of physicians and
public health authorities to connect statements regarding maternal
health with product information deters important interventions
that may help both pregnant women and their unborn children.161
Healthcare providers are well-positioned to explain the
benefits of immunizations against vaccine-preventable diseases
to pregnant women; they have proven their capacity to do so
through their heavy involvement in administrating the H1N1
vaccine to pregnant women during the 2009 pandemic.162
However, research suggests that, broadly speaking, barriers
remain high between providers and vaccinations because of the
fear of adverse pregnancy outcomes and lack of awareness of
national recommendations and product safety information. 163
A 2008 study “analyzed patient and physician knowledge
regarding the influenza vaccine in pregnancy and examined the
impact of several interventions to increase immunization
rates.” 164 Approximately 86% of physicians “stated that they
always recommended vaccinations to their patients” during
prenatal care. 165 When the approximately 14% of physicians who
did not recommend vaccinations were asked via questionnaire
about vaccinations during pregnancy, “25% of physicians said
that there [was] not enough data concerning influenza-related
complications during pregnancy and concerning vaccine
efficacy.” 166 They were also worried about vaccination side
effects and the legal risks of vaccinating pregnant women. 167
However, the most frequent answer was that physicians
understood their patients did not want to be vaccinated
(42.8%). 168
160. Shannon Mulvihill, TDaP Vaccine During Pregnancy? A Difficult Decision for
Any Mom., FOCUS FOR HEALTH, https://www.focusforhealth.org/tdap-vaccine-duringpregnancy-a-difficult-decision-for-any-mom/ [https://perma.cc/YU64-SZ55].
161. See generally Birte Bödeker et al., Skewed Risk Perceptions in Pregnant Women:
The Case of Influenza Vaccination, 15 BMC PUB. HEALTH no. 1308 (2015); Britta Panda et
al., Influenza Vaccination During Pregnancy and Factors for Lacking Compliance with
Current CDC Guidelines, 24 J. MATERNAL-FETAL & NEONATAL MED. 402 (2011).
162. Swamy & Heine, supra note 54, at 213.
163. Id. at 222.
164. See Panda et al., supra note 161, at 403.
165. Id.
166. Id.
167. Id.
168. Id. at 405.
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In the context of influenza, the combination of physician
ambivalence and patient refusal can be fatal. While pregnant
women comprise approximately 1% of the United States
population, they totaled 5% of the deaths caused by H1N1 in the
United States in 2009. 169
Moreover, influenza vaccines
administered during pregnancy may impart important benefits to
newborns as well. A study conducted in Bangladesh suggests that
an influenza shot during pregnancy lowers the risk of influenza
both for the woman and for the baby in the first six months of
life, 170 while a more recent study from South Africa found
vaccination in pregnant HIV-uninfected and HIV-infected
African women was immunogenic and provided protection
against confirmed influenza. 171 “The vaccination was also
effective in HIV-unexposed infants up until 24 weeks after
birth.” 172

2. Product Labeling
A key component of facilitating the communication between
physician and patient with respect to immunizations is what the
physician may say about a vaccine when a pregnant woman asks
about its safety and efficacy profile. 173 Because current clinical
data used for vaccine labeling comes “either from post hoc
analyses of inadvertent exposures during pre-licensure trials
designed to exclude pregnant subjects, or from uncontrolled,
observational postlicensure studies,” 174 physicians may say little
more than what the product insert says along with language
adapted from ACIP or ACOG recommendations. 175
The new PLLR adopted by the FDA and effective as of June
2015 is intended to facilitate meaningful communications
169. Alicia M. Siston et al., Pandemic 2009 Influenza A (H1N1) Virus Illness Among
Pregnant Women in the United States, 303 JAMA 1517, 1522-23 (2010).
170. See generally K. Zaman et al., Effectiveness of Maternal Influenza Immunizations
in Mothers and Infants, 359 NEW ENG. J. MED. 1555 (2008), http://www.nejm.org /doi
/pdf/10.1056/NEJMoa0708630 [http://perma.cc/3L8J-A43Z].
171. Shabir A. Madhi et al., Influenza Vaccination of Pregnant Women and Protection
of Their Infants, 371 NEW ENG. J. MED. 918, 930 (2014), http://www.nejm.
org/doi/full/10.1056/NEJMoa1401480#t=article [https://perma.cc/S7AN-XYSP].
172. Id.
173. See generally Bödeker et al., supra note 161.
174. See Roberts & Gruber, supra note 18, at 967.
175. Id. at 966-67.

740

ARKANSAS LAW REVIEW

Vol. 70:3

between physicians and pregnant and lactating women in a
manner that the old letter-risk system made difficult. 176 But, as
pregnant women are excluded from clinical trials, there is little
manufacturers may do with respect to adapting their current
approaches to product labeling. 177
Pediatrician Saad Omer and obstetrician Richard Beigi
recommend that the FDA issue a “mock label” related to
pregnancy as a guide to help the industry and public health leaders
effectively phase into the new PLLR system and provide
obstetrical care providers clear information. 178 This mock label
should provide guidance for inclusion and format of pregnancyrelated information in sections of the drug labeling that are
specifically relevant to pregnant women. 179 Having clarity
regarding vaccine labeling related to pregnancy “will help ensure
that clinicians have a higher level of confidence in pregnancyrelated vaccines and could provide a road map for conducting
research that can inform labeling and hence clinical decisions.”180

D. Maternal Vaccines: the Future of Healthy Mothers
and Children
This Essay has emphasized that pregnant women are, by
virtue of the structure of medical research norms, effectively
disadvantaged as a group relative to other populations just as they
are in disability jurisprudence, employment, and under other legal
regimes. This disadvantage adversely affects them as pregnant
women (as opposed to, for example, their unborn children). For
example, while the reasons are not well-understood (due to
practices detailed above), pregnant women are at much higher
risk for severe illness and death when infected by certain strains
of influenza. The available medical evidence suggests that
immunization protects them while conferring less relative benefit
upon a newborn. So the constraints on research, labeling, and
physician attitudes are primarily a disadvantage for women.

176. Id.; see generally Requirements for Pregnancy and Lactation Labeling, 79 Fed.
Reg. 72,064 (Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201).
177. See Roberts & Gruber, supra note 18, at 967.
178. Omer & Beigi, supra note 130, at 1227.
179. Id. at 1227-28.
180. Id. at 1228.
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The system also stymies the development of vaccines that
represent the future of infant and early childhood health. It is
nearly impossible to overstate the contribution that childhood
immunizations have made to the lives of children over the last
century:
Diseases that used to be common in [the U.S.] and around
the world, including polio, measles, diphtheria, pertussis
(whooping cough), rubella (German measles), mumps,
tetanus, rotavirus and Haemophilus influenzae type b (Hib)
can now be prevented by vaccination. Thanks to a vaccine,
one of the most terrible diseases in history—smallpox—no
longer exists outside the laboratory. Over the years vaccines
have prevented countless cases of disease and saved millions
of lives. 181

Programs aimed at expanding access to vaccines—
especially childhood immunizations—have enjoyed enormous
global financial support from governments, charities, and
international organizations like UNICEF and the World Health
Organization. “Worldwide, more than 30 vaccine doses are
delivered every second through routine immunization programs.
This number has increased dramatically as more vaccines are
developed . . . and the global community acknowledges that
vaccines, as a fundamental medical intervention, positively affect
more lives than any other.” 182 In 2013, 6.3 million children under
five died, compared with 12.7 million in 1990. Between 1990
and 2013, under-five mortality declined by 49%, from an
estimated rate of 90 deaths per 1000 live births to 46. “The global
rate of decline has also accelerated in recent years—from 1.2%
per annum during 1990-1995 to 4.0% during 2005-2013.” 183 In
other words, the world is nearing universal coverage of children
for known early-childhood immunizations.
Improving the current system for development and licensure
of maternal immunizations is critical not only for public health
emergencies like Zika but also for the next generation of

181. Why Are Childhood Vaccines So Important?, CTRS. FOR DISEASE CONTROL &
PREVENTION (Aug. 18, 2017), http://www.cdc.gov/vaccines/vac-gen/ howvpd.htm
[https://perma.cc/56QQ-YZKA].
182. Berkley, supra note 20, at 179.
183. Millennium Development Goals (MDGs), WORLD HEALTH ORG. (May 2015),
http://www.who.int/mediacentre/factsheets/fs290/en/ [https://perma.cc/2R5Y-5C5G].
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preventative health measures that are likely to make major gains
in children’s health. The first twenty-eight days of life (the
newborn period), are a child’s most vulnerable. 184 In fact,
newborns account for nearly half of all child deaths before five
years of age—about 2.9 million deaths each year. 185 Although
additional childhood and adolescent vaccines are being
developed, immunizations for pregnant women represent a next
step, supported by a great deal of preliminary evidence, in the
effort to ensure that mothers remain healthy during pregnancy and
children are born with as great a chance as possible to lead healthy
lives. Vaccination of women during pregnancy is considered the
most plausible strategy to provide direct antibody protection
against respiratory syncytial virus (RSV), an infection that kills
tens of thousands of infants worldwide annually. 186 The main
limitations on the production of a Group B streptococcus
vaccine—a leading cause of severe invasive disease in young
infants—are not technical or scientific, but regulatory and legal
because they involve a vaccine delivered during pregnancy. 187
Many other promising maternal vaccines that may improve infant
health remain stalled at the conceptual stage. 188
184. Advancing Maternal Immunization, PATH, http://sites.path.org/cvia/ advancingmaternal-immunization/ [https://perma.cc/XVZ2-TCKX].
185. Id.
186. Helen Y. Chu & Janet A. Englund, Maternal Immunization, 59 CLINICAL
INFECTIOUS DISEASES 560, 565 (2014), https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4168293/ [https://perma.cc/JF2G-N457]; Harish Nair et al., Global Burden of Acute
Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A
Systematic Review and Meta-Analysis, 375 LANCET 1545, 1545 (2010),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864404/ [https://perma.cc/E7FH-7N FR].
187. Clare L. Cutland et al., Increased Risk for Group B Streptococcus Sepsis in Young
Infants Exposed to HIV, Soweto, South Africa, 2004-2008, 21 EMERGING INFECTIOUS
DISEASES 638, 638 (2015) (“We estimate that use of trivalent GBS vaccine (serotypes Ia, Ib,
and III) could prevent 2,105 invasive GBS cases and 278 deaths annually among infants in
South Africa; therefore, vaccination of all pregnant women in this country should be
explored.”), https:// wwwnc.cdc.gov /eid /article/ 21/ 4/ 14-1562_article [https://perma.cc/
X265-3DWW]; Paul T. Heath & Robert G. Feldman, Vaccination Against Group B
Streptococcus, 4 EXPERT REV. VACCINES 207, 207 (2005), https:// www.ncbi.nlm.nih.gov
/pubmed /15889994 [https:// perma.cc/9JGV-X9ZQ ] (“The main limitations on the
production of a Group B streptococcus vaccine are not technical or scientific, but regulatory
and legal.”).
188. See CLINICAL DEVELOPMENT, supra note 58, at 3 (“Scientific advances and
increasing recognition of unmet potential have led to a recent surge in activity and interest
in maternal immunization.”); Richard Beigi et al., Maternal Immunization: Opportunities for
Scientific Advancement, 59 CLINICAL INFECTIOUS DISEASES S408, S412 (2014),
https://www.ncbi.nlm.nih.gov/pubmed/25425719 [https://perma.cc/W8AP-GVFV].
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V. CONCLUSION
Legal scholars are undertaking a crucial and comprehensive
review of laws aimed at protecting pregnant women from
discrimination, arguing for improvement of laws in place to
support the multiple factors that affect healthy pregnancies, and
urging a more comprehensive view of pregnancy to inform lawmaking generally. This Essay has suggested that there is as great
or greater a need to apply these critiques to the process that leads
to lifesaving vaccines for pregnant women, improves meaningful
communication between pregnant women and their healthcare
providers, and opens the window to the next advances in
individual and public health that will secure healthy lives for
children. Vaccine-preventable diseases associated with adverse
maternal, fetal, or infant health may be prevented by
immunization during pregnancy. As immunizations like MMR,
Tdap, and polio reach the world’s poorest children and coverage
rates in developed countries move higher, the next generation of
immunizations will be those for which administration during
pregnancy imparts health benefits to both mothers and children
that are not realizable either before or after pregnancy.

